July 12, 1993Archives of Internal Medicine
Subcutaneous Low-Molecular-Weight Heparin Compared With Continuous IntravenoUnfractionated Unfractionated Heparin in the Treatment of Proximal Deep Vein Thrombosis
Why the study?
Does fixed-dose subcutaneous enoxaparin improve thrombus size reduction compared to continuous intravenous unfractionated heparin in patients with proximal deep vein thrombosis?
Population
134 patients with proximal deep vein thrombosis (67 per group)
Comparison
Fixed-dose subcutaneous enoxaparin twice daily… vs Adjusted-dose intravenous unfractionated heparin…
Design
RCT, randomized
Follow-up
10 days
Authors
Discussion
Loading...
Member takes
Implication
Supports enoxaparin over UFH for proximal DVT; confirms LMWH superiority for early thrombus resolution in this RCT.
Structured PICO
Does fixed-dose subcutaneous enoxaparin improve thrombus size reduction compared to continuous intravenous unfractionated heparin in patients with proximal deep vein thrombosis?
P
Population
134 patients with proximal deep vein thrombosis (67 per group)
I
Intervention
Fixed-dose subcutaneous enoxaparin twice daily for the initial 10 days
C
Comparator
Adjusted-dose intravenous unfractionated heparin (UFH) by continuous infusion for the initial 10 days
O
Outcome
Change of the size of the thrombus assessed by repeated venograms between day 0 and day 10surrogate
Subcutaneous enoxaparin is superior to continuous intravenous unfractionated heparin in reducing thrombus size and preventing recurrent thromboembolic events in patients with proximal deep vein thrombosis.
Cite This Study
Gérald Simonneau (1993) studied this question.